Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems

British Journal of Clinical Pharmacology

Volumn 63, Issue 2, 2007, Pages 187-195

  Viktil, Kirsten K ^a,b   Blix, Hege S ^a   Moger, Tron A ^a   Reikvam, Aasmund ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Drug related problems; Hospitalized patients; Polypharmacy

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARMACIST; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOLOGY;

AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; EVALUATION STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY;

EID: 33846110894     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02744.x     Document Type: Article

References (39)

1. Buckley BM. Healthy ageing: ageing safely. Eur Heart J 2001; 3 (Suppl. N): N6-10.
2. Geest SD, Steeman E, Leventhal ME, Mahrer-Imhof R, Hengartner-Kopp B, Conca A, Bernasconi AT, Petry H, Rocca HB-L. Complexity in caring for an ageing heart failure population: concomitant chronic conditions and age related impairments. Eur J Cardiovasc Nurs 2004; 3: 263-70.
3. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005; 17: 123-32.
4. Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 2005; 31: 4-11.
5. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997; 53: 7-11.
6. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 2005; 25: 1636-45.
7. Brager R, Sloand E. The spectrum of polypharmacy. Nurse Pract 2005; 30: 44-50.
8. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26.
9. Williams ME, Pulliam CC, Hunter R, Johnson TM, Owens JE, Kincaid J, Porter C, Koch G. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc 2004; 52: 93-8.
10. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001; 35: 835-40.
11. Flaherty JH, Perry HM III, Lynchard GS, Morley JE. Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci 2000; 55: M554-M559.
12. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809-17.
13. Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35: 1004-9.
14. Viktil KK, Enstad M, Kutschera J, Smedstad LM, Schjott J. Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharmacy World Sci 2001; 23: 153-8.
15. Alarcon T, Barcena A, Gonzalez-Montalvo JI, Penalosa C, Salgado A. Factors predictive of outcome on admission to an acute geriatric ward. Age Ageing 1999; 28: 429-32.
16. Viola R, Csukonyi K, Doro P, Janka Z, Soos G. Reasons for polypharmacy among psychiatric patients. Pharm World Sci 2004; 26: 143-7.
17. Perri M III, Menon AM, Deshpande AD, Shinde SB, Jiang R, Cooper JW, Cook CL, Griffin SC, Lorys RA. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother 2005; 39: 405-11.
18. Christensen D, Trygstad T, Sullivan R, Garmise J, Wegner SE. A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 2004; 2: 248-56.
19. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ 2003; 327: 712-7.
20. Jyrkka J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study. Eur J Clin Pharmacol 2006; 62: 151-8.
21. Fincke BG, Snyder K, Cantillon C, Gaehde S, Standring P, Fiore L, Brophy M, Gagnon DR. Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Safety 2005; 14: 121-8.
22. Klarin I, Fastbom J, Wimo A. A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. Pharmacoepidemiol Drug Safety 2003; 12: 669-78.
23. Kennerfalk A, Ruigomez A, Wallander MA, Wilhelmsen L, Johansson S. Geriatric drug therapy and healthcare utilization in the United kingdom. Ann Pharmacother 2002; 36: 797-803.
24. Ikaheimo P, Hartikainen S, Tuuponen T, Kiuttu J, Klaukka T. Comorbidity and medication load in adult asthmatics. Scand J Prim Health Care 2005; 23: 88-94.
25. Fastbom J. Increased consumption of drugs among the elderly results in greater risk of problems. Lakartidningen 2001; 98: 1674-9.
26. Pitkala KH, Strandberg TE, Tilvis RS. Is it possible to reduce polypharmacy in the elderly? A randomised, controlled trial. Drugs Aging 2001; 18: 143-9.
27. Trygstad TK, Christensen D, Garmise J, Sullivan R, Wegner SE. Pharmacist response to alerts generated from medicaid pharmacy claims in a long-term care setting: results from the North Carolina Polypharmacy Initiative. J Manag Care Pharm 2005; 11: 575-83.
28. Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med 2004; 164: 1957-9.
29. Jackson HD, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57: 231-6.
30. Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. Ann Pharmacother 2005; 39: 1785-91.
31. Sloane PD, Gruber-Baldini AL, Zimmerman S, Roth M, Watson L, Boustani M, Magaziner J, Hebel JR. Medication undertreatment in assisted living settings. Arch Intern Med 2004; 164: 2031-7.
32. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338: 1516-20.
33. WHO Collaboratoring Centre for Drug Statistics Methodology. ATC Classification Index with DDDs. Oslo: WHO Collaborating Centre 2002.
34. van Mil F, ed. Proceedings of the International Working Conference on Outcomes Measurements in Pharmaceutical Care. Hilleroed, Denmark: Pharmaceutical Care Network Europe (PCNE) 1999: 9: 84.
35. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP 1990; 24: 1093-7.
36. Viktil KK, Blix HS, Reikvam A, Moger TA, Hjemaas BJ, Walseth EK, Vraalsen TF, Pretsch P, Jorgensen FI. Comparison of drug-related problems in different patient groups. Ann Pharmacother 2004; 38: 942-8.
37. Blix HS, Viktil KK, Reikvam A, Moger TA, Hjemaas BJ, Pretsch P, Vraalsen TF, Walseth EK. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol 2004; 60: 651-8.
38. Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, Park TR, Kuehl AK. Evaluation of the Iowa Medicaid Pharmaceutical Case Management Program. J Am Pharm Assoc 2004; 44: 337-49.
39. Koecheler JA, Abramowitz PW, Swim SE, Daniels CE. Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. Am J Hosp Pharm 1989; 46: 729-32.